Analysts expect that Bruker Co. (NASDAQ:BRKR) will report sales of $544.53 million for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Bruker’s earnings. The highest sales estimate is $546.81 million and the lowest is $542.30 million. Bruker posted sales of $530.50 million during the same quarter last year, which indicates a positive year over year growth rate of 2.6%. The company is scheduled to announce its next earnings results on Thursday, February 14th.
On average, analysts expect that Bruker will report full year sales of $1.89 billion for the current year, with estimates ranging from $1.88 billion to $1.89 billion. For the next year, analysts expect that the firm will post sales of $1.96 billion, with estimates ranging from $1.95 billion to $1.97 billion. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Bruker.
Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Thursday, November 1st. The medical research company reported $0.37 EPS for the quarter, topping the consensus estimate of $0.30 by $0.07. Bruker had a return on equity of 27.46% and a net margin of 5.24%. The business had revenue of $466.60 million during the quarter, compared to analyst estimates of $451.88 million. During the same period last year, the business posted $0.29 earnings per share. The company’s quarterly revenue was up 7.1% on a year-over-year basis.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc raised its stake in shares of Bruker by 1.0% in the third quarter. Vanguard Group Inc now owns 10,210,783 shares of the medical research company’s stock valued at $341,550,000 after acquiring an additional 101,913 shares in the last quarter. Vanguard Group Inc. raised its stake in Bruker by 1.0% in the third quarter. Vanguard Group Inc. now owns 10,210,783 shares of the medical research company’s stock valued at $341,550,000 after buying an additional 101,913 shares in the last quarter. BlackRock Inc. raised its stake in Bruker by 1.7% in the second quarter. BlackRock Inc. now owns 5,358,747 shares of the medical research company’s stock valued at $155,618,000 after buying an additional 91,058 shares in the last quarter. AQR Capital Management LLC raised its stake in Bruker by 28.4% in the third quarter. AQR Capital Management LLC now owns 2,243,794 shares of the medical research company’s stock valued at $75,055,000 after buying an additional 496,259 shares in the last quarter. Finally, Janus Henderson Group PLC raised its stake in Bruker by 4,114.9% in the third quarter. Janus Henderson Group PLC now owns 2,014,706 shares of the medical research company’s stock valued at $67,392,000 after buying an additional 1,966,906 shares in the last quarter. Institutional investors and hedge funds own 64.85% of the company’s stock.
BRKR opened at $33.37 on Friday. Bruker has a 52 week low of $26.10 and a 52 week high of $36.38. The firm has a market cap of $5.06 billion, a PE ratio of 27.45, a PEG ratio of 1.79 and a beta of 1.35. The company has a quick ratio of 1.32, a current ratio of 2.24 and a debt-to-equity ratio of 0.27.
The business also recently disclosed a quarterly dividend, which was paid on Friday, December 21st. Stockholders of record on Monday, December 3rd were paid a $0.04 dividend. This represents a $0.16 annualized dividend and a dividend yield of 0.48%. The ex-dividend date of this dividend was Friday, November 30th. Bruker’s payout ratio is currently 13.22%.
Bruker Company Profile
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
Recommended Story: Call Option
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.